Cargando…
Nonsense on Stilts – Part 1: The ICER 2020-2023 Value Assessment Framework for Constructing Imaginary Worlds
Previous commentaries in the Formulary Evaluation section of INNOVATIONS in Pharmacy have pointed to the lack of credibility in modeled claims for cost-effectiveness and associated recommendations for pricing and access by the Institute for Clinical and Economic Review (ICER). The principal objectio...
Autor principal: | Langley, Paul C |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
University of Minnesota Libraries Publishing
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8132519/ https://www.ncbi.nlm.nih.gov/pubmed/34017624 http://dx.doi.org/10.24926/iip.v11i1.2444 |
Ejemplares similares
-
ICER, ISPOR AND QALYs: Tales of Imaginary Worlds
por: Langley, Paul C
Publicado: (2019) -
CVS Health and the Imaginary Worlds of the Institute for Clinical and Economic Review (ICER)
por: Langley, Paul C
Publicado: (2018) -
Another Rush to Judgment: The Imaginary Worlds of ICER and Recommendations in Duchenne Muscular Dystrophy
por: Langley, Paul C
Publicado: (2019) -
More Unnecessary Imaginary Worlds – Part 2: The ICER Evidence Report on Modeling Oral Semaglutide for Type 2 Diabetes
por: Langley, Paul C
Publicado: (2020) -
More Unnecessary Imaginary Worlds – Part 4: The ICER Evidence Report for Crizanlizumab, Voxelotor and L-Glutamine for Sickle Cell Disease
por: Langley, Paul C
Publicado: (2020)